Navigating the neurochemical space by computer-aided molecular design

April 6, 2012
Navigating the neurochemical space by computer-aided molecular design

Pharmaceutical scientists from VU University Amsterdam and colleagues from the University of Vienna and Medical University of Vienna have gained new insights into the molecular basis of the GABAA receptors, an important class of brain receptor involved in regulating the excitation of nerve cells. Their results were published online on March 25 in the prestigious journal Nature Chemical Biology.

GABAA receptors are the major inhibitory receptorsin the brain and the site of action of a variety of clinically important drugs against epilepsy, anxiety and . VU scientists Chris de Graaf and Iwan de Esch from the Division of Medicinal Chemistry and their colleagues developed three-dimensional structural models of the GABAA receptor with computer-aided molecular design. They predicted that novel molecules (neurochemicals)canbind to the receptor in the same manner as known drugs like benzodiazepines (Diazepam)can. Based on previously known ligand binding hypotheses, the consortium used computer simulationst o select a small set of molecules from large chemical libraries. Laboratory experiments confirmed that the predicted novel small molecules can indeed modulate the activity of the GABAA receptor.

Some of these novel neurochemicals are relatively small, making them attractive starting points for so-called Fragment-Based Drug Discovery (FBDD). This methodology has the potential to develop new medicines more efficiently than high-throughput screening. In recent years, the Division of has set up a dedicated FBDD research line to develop new biologically active compounds. New drug targets are probed by screeningsmall fragments using innovative technologies. The group is tackling drug targets embedded in cell membranes, such as G-protein coupled receptors (GPCRs) and ligand-gated ion channels (LGICs), like the GABAA receptor. The customized computer-aided fragment screening approach used in this study supports the validity of thebinding between GABAAand its ligands. Moreover, it paves the way for efficient structure based drug design and possibly novel drugs against epilepsy, anxiety and sleep disorders.

Explore further: A step forward in targeted pain therapy

More information: Richter, L.; et al. Diazepam-bound GABAAreceptor modelsidentify new benzodiazepine binding-site ligands. Nature Chemical Biology.

Related Stories

A step forward in targeted pain therapy

January 22, 2008

Our bodies sense painful stimuli through certain receptors located in the skin, in joints and many internal organs. Specialized nerve fibers relay these signals coming from the periphery to the brain, where pain becomes conscious. ...

Recommended for you

A new form of real gold, almost as light as air

November 25, 2015

Researchers at ETH Zurich have created a new type of foam made of real gold. It is the lightest form ever produced of the precious metal: a thousand times lighter than its conventional form and yet it is nearly impossible ...

Getting under the skin of a medieval mystery

November 23, 2015

A simple PVC eraser has helped an international team of scientists led by bioarchaeologists at the University of York to resolve the mystery surrounding the tissue-thin parchment used by medieval scribes to produce the first ...

Moonlighting molecules: Finding new uses for old enzymes

November 27, 2015

A collaboration between the University of Cambridge and MedImmune, the global biologics research and development arm of AstraZeneca, has led researchers to identify a potentially significant new application for a well-known ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.